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ABSTRACT 
Breast cancer (BC) is the most common form of cancer in western women. The grand 
majority of the afflicted women are eligible for endocrine treatment. Tamoxifen has 
been the golden standard treatment for more than three decades. Unfortunately, 
resistance towards this drug is a major concern in the clinic. The aim of this thesis is to 
increase our knowledge of the resistance mechanisms by merging information from cell 
model systems and human tumors. 
 
One of the main inducers of angiogenesis, vascular endothelial growth factor (VEGF), 
is overexpressed in many types of cancers and has also been associated to poor 
outcome in estrogen receptor (ER) positive BC. When analyzing VEGF in 404 ER 
positive tumors from patients treated with tamoxifen as the sole adjuvant treatment, we 
found a significant negative effect of high VEGF on survival. Interestingly, the effect 
was overcome by a prolonged tamoxifen regimen. Moreover, studies on MCF7 cells 
and its 4-hydroxytamoxifen (4-OHT)-resistant counterpart, MCF/LCC2 (LCC2) 
revealed the existence of an autocrine signaling loop involving VEGF, its receptor 
VEGFR2 and p38 in LCC2 cells.  
 
As the resistance mechanism likely involves alterations in multiple parts of the 
signaling machinery we used a high throughput methodology to study this further. We 
performed quantitative mass spectrometry (MS)-based proteomics on these cell lines to 
explore key proteomic differences between them and in response to 4-OHT treatment. 
Pathway analysis on significantly deregulated proteins revealed a connection to the 
retinoic acid receptor alpha (RARA), a receptor in close interaction with ER signaling. 
The 4-OHT-resistant cells exhibited attenuated anti-growth response in response to 
RARA activation in contrast to MCF7 cells. LCC2 cells were also dependent on RARA 
for maintenance of viability. Primary validation of the impact of RARA on survival, in 
the previously described cohort, revealed a correlation between high RARA expression 
and reduced relapse-free survival specifically in those treated with two years of 
tamoxifen. Moreover, VEGF was highly correlated to RARA expression. We conclude 
that RARA may be of potential prognostic or predictive value for patients eligible for 
tamoxifen therapy. 
 
We used a similar MS-based proteomics approach in order to discover potential 
biomarkers predictive for tamoxifen response by comparing patients with early relapse 
(<2years) versus non-relapse (>7years). This pilot study of 24 patients yielded in the 
identification of 3101 proteins out of which 13 were classified as characteristic for 
tamoxifen-resistant tumors. CAPS and MX1 are part of this 13-protein signature and 
have shown to be overexpressed in patients with early relapses. 
 
Altogether, our findings suggest that it is possible to apply information from cell lines 
to find patient-based associations with potential clinical utility. The response to 
tamoxifen may be dependent on the involvement of VEGF and RARA. The predictive 
value of CAPS and MX1 remains to be elucidated. The validation of these factors in 
larger patient populations is expected in the near future.  
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1 INTRODUCTION 
 
Despite all our efforts to combat cancer and improve its treatment, cancer mortality is 
still high causing approximately 7.6 million deaths around the world per year [1]. In the 
fight of prolonging a patient’s life the quality of life is to some extent put aside. It is 
important not to forget that we are dealing with patients who desire a better quality of 
life above all. The dream of personalized medicine is to adjust therapy so that the right 
drug is given to the right patient at the right time. By doing so, we would also improve 
the effects of a specific drug and spare patients from ineffective treatments with severe 
side-effects. This work aims to show that although we are taking small steps towards 
this dream it is possible to achieve it. 
 
1.1 BREAST CANCER 
1.1.1 General overview 
A prolonged period of time from the first menstruation to menopause thus prolonging 
the exposure to endogenous estrogen (E2) is strongly associated with breast cancer 
(BC) although contradictions have been reported [2]. What we also have to consider is 
that as our society evolves our way of living changes with all that comes with it such as 
an increased exposure and consumption to toxins, less physical activity and imbalanced 
nutrition etc. Despite this, medical advancement is allowing us to reach a high age but 
at what price? Some would probably argue that it is against nature itself to become as 
old as we are able to become nowadays, explaining why cancer would probably be 
nature’s way of getting rid of us. High age is actually one of the main risk factors for 
BC and cancer in general [3]. These factors together with improved diagnosis are the 
main reasons to an increase in BC cases in developed countries. As less developed 
countries adapt to a similar lifestyle the incidence of BC is rapidly increasing. 
Moreover, economical limitation, lack of awareness and cultural beliefs in less 
developed countries contribute to the poor diagnosis of BC at an early stage thus 
resulting in higher BC-related deaths.  
 
Worldwide, it is estimated that one million women are diagnosed with BC every year 
and approximately 40 % die from their disease [4]. In Sweden only, there were 7000 
cases reported in 2007 constituting 30% of all cancer cases in women. Fortunately, 
early diagnosis, social awareness and proper treatment have made it possible to achieve 
a relative 10-year survival of 80% [3]. 
 
1.1.2 Clinical grading and staging 
BC is a very heterogeneous disease comprising a wide range of subtypes which 
pathologists have had a tough time trying to classify. The most common histological 
type of BC is adenocarcinoma, that is, cancer originating in mammary epithelial cells. 
Within this group there are, according to the World Health Organization (WHO) 
classification, 18 different types out of which ductal invasive BC of no special type is 
the most common [5]. The classification according to histopathological features lacks 
prognostic information and does consequently not influence the choice of therapy [6]. 
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Grading and staging describe the characteristics of the tumor more in detail as they 
determine its differentiation, proliferative activity and aggressiveness. Histological 
grading takes the differentiation level of cells into account dividing them into a low 
grade group, when they are well differentiated and slow growing, an intermediate 
group and high grade group, when they are poorly differentiated and rapidly growing 
(Bloom-Richardson). The Nottingham grading system (NGS) (Elston-Ellis 
modification of Bloom-Richardson) which is based on the degree of tubule or gland 
formation, nuclear pleomorphism and mitotic count, takes the evaluation of the 
morphology of cells to a more detailed level making it the most recommended system 
for BC worldwide [7]. 
 
Stage 
Relative 
Survival 
(5y) 
TNM classification 
0 Tis N0 M0 93% 
Tumor size 
TX Cannot be assessed 
T0 No evidence of primary tumor 
I T1 N0 M0 88% 
Tis 
Carcinoma in situ (lobular or ductal) or Paget’s 
disease of the nipple with no associated tumor 
T1 ≤2cm 
T2 ≥2cm but ≤ 5cm 
IIA 
T0 N1 M0 
T1 N1 M0 
T2 N0 M0 
81% 
T3 ≥5cm 
T4 
Tumor of any size with direct extension to chest wall 
or skin or both of the above. 
IIB 
T2 N1 M0 
T3 N0 M0 
74% 
Lymph node 
NX Cannot be assessed 
N0 Cancer has not spread to nearby lymph nodes 
IIIA 
T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1-2 M0 
67% 
N1 
Cancer has spread to the movable ipsilateral axillary 
lymph nodes 
N2 
Cancer has spread to ipsilateral lymph nodes fixed to 
one another or to other structures under the arm 
IIIB 
T4 any N M0 
any T N3 M0 
41% 
N3 
Cancer has spread to the ipsilateral mammary lymph 
node (s) 
Metastases 
IIIC Any T N3 M0 49% 
MX Cannot be assessed 
M0 No distant metastasis 
IV Any T any N M1 15% 
M1 
Distant metastasis present (includes ipsilateral 
supraclavicular lymph nodes) 
 
Table 1. Staging and survival of BC using guidelines from the Tumor Node Metastasis (TNM) 
classification system. (Adapted and modified from the National Cancer Institute and the 
National Cancer Data Base) 
 
BC is staged by using the classical tumor node metastasis (TNM) classification based 
on four characteristics such as size, invasiveness, involvement of lymph nodes and 
presence of metastases and expressed as a number between 0 and 4 in roman letters 
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(Table 1). Although morphological evaluation is of importance, staging is one of the 
most important factors when selecting appropriate treatment for the patient. However, 
as technological advances feeds us with increasing knowledge in tumor biology it is of 
great importance to incorporate this information and update the present guidelines. That 
is why the latest edition of the American Joint Committee on Cancer (AJCC) cancer 
staging manual includes guidelines for standardization as well as implementation of 
available electronic analytical tools [8]. Moreover, the rules on TNM staging have been 
more clearly specified to reduce misinterpretations. Importantly, the MX category 
describing an unknown metastatic status has been removed and should be replaced by 
M0 [8].  
 
The employment of high throughput technologies such as gene microarrays has enabled 
further characterization and classification of different subgroups of BC based on gene 
expression. The work of Perou et al enabled the classification of invasive carcinomas 
into five subtypes, two ER positive (luminal A and B), and three ER negative (HER2-
enriched, normal breast-like and basal-like) [9]. There is so far no validated consensus 
in how to distinguish Luminal A, which is the most represented in BC, from Luminal 
B. Although both types are positive for progesterone receptor (PR) expression, Luminal 
A is the slower proliferating of the two [10]. In addition to high HER2 expression the 
HER2-enriched type is also defined by elevated expression of various genes close to 
the HER2 amplicon. The normal breast-like subtype exhibits high expression of genes 
characteristic of non-epithelial cell types and adipose tissue-related. The basal-like 
type, also called triple negative (ER-/PR-/HER2-) expresses keratins 5, 6 and 17 
similarly to basal epithelial cells of the normal mammary gland, as well as laminin and 
fatty acid binding protein 7 [9]. Similarly, a subtype with the additional trait of low 
expression of cell-cell adhesion-related genes, hence the name, Claudin-low subtype 
was recently characterized. Moreover, it has been shown to be enriched with stem-like / 
mesenchymal characteristics and to be of poor prognosis. Although the basal-like and 
Claudin-low exhibit similar biology their difference in response to treatment remains to 
be elucidated [11].     
 
1.1.3 Prognostic and predictive markers 
 
A prognostic marker is used to acquire an insight into the natural progression of the 
disease without treatment by identifying patients with different risks of outcome.  A 
predictive marker is an indicator of sensitivity or resistance to a specific treatment. In 
short, prognostic markers tell if a patient needs treatment whereas the predictive marker 
tells which treatment will be the most optimal. Needless to say, these types of markers 
are of great importance in the management of the disease.  
 
At present, the established prognostic and predictive markers available in BC are ER, 
PR, HER2, age, tumor size, lymph node status and histological grade. 
 
ER and HER2 are the best established markers available to oncologists as they decide if 
and which treatment would be the most appropriate for their patients. In fact, these two 
markers are the only BC markers so far having reached level of evidence I or II 
according to the American Society of Clinical Oncology’s Tumor Marker Utility 
Grading System. ER and HER2 expression are evaluated routinely in every BC. Since 
approximately 80% of all BC tumors express the alpha isoform of ER, often simply 
referred as ER, it is a marker of great impact. ER is considered a key marker for 
endocrine therapy response although with a limited prognostic value. The extensive 
evaluation by the early BC trialists’s collaborative group (EBCTCG) concluded that 
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endocrine therapy is of greater benefit for patients with ER positive BC tumors whereas 
no benefit was observed in ER negative BC. Interestingly, a small benefit was seen in 
patients with an ER negative and PR positive disease [12]. The degree of ER 
expression has also been shown to influence therapy response as higher levels of ER 
were related to improved outcome to endocrine therapy [13]. 
It has been shown that PR is strongly dependent to ER expression. In spite of this, the 
predictive significance of PR is poor. However, adjuvant trials comparing endocrine 
treatment with controls indicate a strong prognostic value of PR expression [14]. It is 
suggested that the  isoform of ER could be of potential prognostic and predictive 
value. Although ER is structurally similar to ER it is believed to mediate opposite 
effects, explaining its downregulation in BC. Surprisingly, ER expression was found 
to be associated with poor prognosis and endocrine resistance. Due to various 
contradicting reports, ER it has still a long way to go before it qualifies as a reliable 
marker [15].   
 
HER2, a member of the epidermal growth factor receptor (EGFR) family, has been 
shown to be both a prognostic and predictive marker in BC. About 15 % of all BCs 
overexpress HER2 and thus likely to have a poor outcome. This group of patients is, 
however, expected to benefit from HER2 targeting therapy [16]. There have been some 
issues with accuracy and reproducibility of ER, PR and HER2 determination and 
recently an expert panel from the American Society of Clinical Oncology and College 
of American Pathologists (ASCO/CAP) provided recommendations for the testing of 
these three markers for optimized methodology, interpretation and reporting of 
established assays [17]. The suggested definition of ER and PR positivity as a staining 
of at least 1% positive tumor nuclei will help avoid false negative evaluations [18]. To 
date, some countries including Sweden still use 10% as cut-off point. 
 
BC is a disease of the elderly. Nevertheless, 1 in every 8 invasive BCs is found in 
women below 45 years of age and is often of poor prognosis. Tumor size and lymph 
node status are considered strong prognostic markers. They both correlate to each other 
suggesting that the larger the tumor the higher the risk of nodal involvement [19]. 
However, it is important to keep in mind that lymph node status does not reflect the 
behavior of a tumor entirely correctly [19, 20].  
 
Although histological grading using the NGS alone identifies groups of different 
prognosis it has been shown to be limited since the intermediate group of grade II 
tumors can further be separated into a low and high grade by use of gene array analyses 
[21]. Studies have demonstrated that grade is an independent prognostic factor in 
specific subgroups of BC, including ER-positive and HER2 negative BC [22]. 
Importantly, the NGS has been incorporated in Adjuvant! Online and the St Gallen 
guidelines for use of adjuvant treatment [23]. However, the lack of reproducibility in 
general has been an issue of discussion. 
 
The technological advancement in high-throughput microarray-based gene-expression 
methods has enabled the identification of various multi-gene signatures associated with 
prognosis. However, only a few have been appropriately validated. Oncotype Dx® has 
been shown to correlate with outcome, and also is also of predictive potential for 
endocrine therapy and chemotherapy [24]. Other successful gene signatures are the 
Mamaprint®, intended for the identification of patients with poor outcome [25] and the 
Rotterdam profile for the identification of patients likely to benefit from tamoxifen 
[26]. Actually, the value of Oncotype Dx® and Mamaprint® as superior prognostic 
tools is currently under investigation in large prospective randomized clinical trials 
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(TAILORx and MINDACT) [7]. In addition to all the factors discussed above there are 
some other factors of prognostic and predictive use which are not equally well 
established such as assessment of proliferation rate by Ki67, synthesis phase fraction 
(SPF), CyclinD1 and Cyclin E [15]. 
 
1.1.4 Treatment modalities  
 
Treatment of BC is determined by the evaluation of prognostic and predictive markers. 
Furthermore, treatment approaches are classified according to how they act and at what 
phase of treatment they are given. The various therapy approaches are often used in 
combination. Generally patients are subjected to surgery and after that often eligible for 
additional treatment, i.e. adjuvant therapy, in order to avoid recurrence of disease. 
Neoadjuvant therapy, which previously was used to reduce tumor size if it was 
considered too large for surgery, is now being used at a higher extent since it gives 
direct feedback on the efficacy of treatment.     
 
Surgery is still the most commonly used treatment strategy in BC patients. For a long 
time, BC was considered a local disease and therefore the only type of treatment 
offered to women with BC was the removal of the whole breast i.e., mastectomy. The 
original mastectomy advocated by William Hallstedt was a very aggressive surgery 
often resulting in severe side effects and metastatic recurrence [27]. BC surgical 
techniques have evolved since then into more breast conserving ones, including 
lumpectomies and quadrantectomies, in which only parts of the breast are taken away. 
Metaanalyses of various randomized trials showed that radiotherapy as supplementary 
treatment to surgery was superior to surgery alone in terms of recurrence risk and 15-
year survival [28]. Moreover, improved radiotherapy methods involving more precise 
dose planning and delivery and have increased local control and reduced cardiac 
damage, a previously common adverse effect of BC radiotherapy [29, 30]. 
  
BC chemotherapy is often used as an adjuvant therapy with the purpose to eradicate 
possible micrometastases in any part of the body. Moreover, chemotherapy given to BC 
patients often includes drugs with different mechanisms of action.  This multidrug-
approach often results in synergistic effects of the drugs as well as reduced cytotoxicity 
as lower doses may be given. Following the pivotal CMF (Cyclophosphamide, 
Methotrexate and 5-Fluorouracil)  several combinations are currently in clinical use, of 
which the most commonly used regimens include FEC or FAC (Epirubicin or 
Adriamycin) either followed by a taxane [12, 31].  
 
The development of humanized antibodies inhibiting the growth factor receptor HER2, 
trastuzumab, was the turning point for targeted therapy. Since then it has been shown 
effective in reducing BC recurrence in a specific group of patients. Moreover, receiving 
1 year of trastuzumab after completed primary treatment was shown to decrease the 
rate of recurrence by 50% [32]. As the impact on trastuzumab response through various 
downstream pathways, such as the phosphatidylinositol 3 kinase (PI3K) and mitogen 
activating protein kinase (MAPK), was uncovered, small molecular inhibitors have 
been considered alone or in combination with trastuzumab or chemotherapy. Several 
inhibitors targeting other BC-related proteins have been developed. However it is still 
too early to predict their impact on BC therapy [33].  
 
Another therapy approach used adjuvantly includes endocrine therapy which aims to 
deprive BC cells from E2 as some of them need it for their survival. Suppression of E2 
production is acquired by ovarian ablation (surgical or pharmacological) in 
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premenopausal patients [34] or by aromatase inhibitors (AIs) in post-menopausal 
women as most part of E2 is acquired from the conversion of androgens in peripheral 
tissues by the action of the aromatase enzyme [35]. The AIs in use are examestene, 
anastrozole and letrozole and have all been proved to be of benefit for postmenopausal 
patients [36].  
 
Another approach of inhibiting E2 signaling is to antagonize ER function by using 
either of two principal strategies, such as downregulation or selective modulation of ER 
signaling by ER downregulators (ERDs) and selective ER modulators (SERMs), 
respectively. With respect to ERDs, Fulvestrant is the only one in clinical use and 
classified as a second-line hormone-based treatment choice for post-menopausal 
women with advanced hormone-receptor-positive BC [37]. At present, there are three 
SERMs which have been tested for clinical use i.e., Tamoxifen, raloxifen, toremifen 
and of these tamoxifen is the best characterized one and also the only one currently in 
use in clinical practice of BC [38]. Tamoxifen has been in use for more than three 
decades having been successful in the treatment of both pre and postmenopausal 
women with BC and also in preventive purposes for women at elevated risk. In a 
survey conducted by EBCTCG,
 
it was found that a 5-year use of tamoxifen in women 
with ER positive BC reduces the BC associated death rate by approximately 31%, 
regardless of age [12]. However, the ASCO guidelines from 2010 regarding endocrine 
therapy in post-menopausal patients recommend the use of AIs either upfront or after 
tamoxifen treatment for a maximum of five years for improve outcome [36].  
Moreover, for premenopausal patients, the use of goserelin in addition to tamoxifen or 
exemestene is suggested to be more beneficial than tamoxifen alone and is currently 
under investigation in international randomized phase III trials [34].  
 
1.2 TAMOXIFEN  
 
Tamoxifen acts a competitive inhibitor of ER. Normally, E2 binds to the ligand binding 
domain (LBD) of ER thus activating the activation function 2 (AF-2) located nearby 
and promoting dimerization with another ER. The activation induces conformational 
changes of the LBD enabling dimerization and recruitment of co-activators e.g. SRC-3 
and transcription factors e.g. AP-1 [39, 40]. This enables the binding of the complex to 
estrogen responsive elements (ERE) located on DNA ultimately inducing the 
transcription of target genes which transduce the proliferative signaling of E2. The 
binding of tamoxifen promotes conformational changes different to that of E2 enabling 
the recruitment of transcriptional repressors instead thus resulting in transcriptional 
inhibition [39]. Apart from its antiestrogenic characteristic tamoxifen has also been 
shown to interact with protein kinase C and affect calcium signaling by binding to 
calmodullin [41]. Moreover, tamoxifen is known to cause an arrest in the early phase of 
cell cycle, G1 [42]. 
 
1.2.1 Mechanisms of resistance 
 
Although introducing tamoxifen into the treatment of BC significantly reduced BC-
related deaths among women, resistance to tamoxifen is a major concern. Some BC 
patients exhibit tamoxifen resistance already in the beginning of treatment (intrinsic 
resistance) whereas others develop resistance during the course of the treatment 
(acquired resistance). Several parts of the cell signaling apparatus have been identified 
as potential contributors to the resistance.  
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1.2.1.1 Drug metabolism  
Tamoxifen is metabolized into active compounds such as endoxifene and 4-
hydroxytamoxifen in order to exert a more potent effect. There are a variety of enzymes 
in the cytochrome P450 system involved in these steps. CYP2D6 is the enzyme 
mediating the conversion of N-desmethyl-tamoxifen into endoxifene [43]. Variations of 
the CYP2D6 allele have been associated to different enzyme activity or expression and 
thus affecting the ability to metabolize the drug [44].   
 
1.2.1.2 Altered Estrogen Receptor signaling 
Being the main marker for eligibility to endocrine therapy it was believed that 
resistance could be caused by ER mutations and splice variants. However, despite 
much investigation their clinical role in outcome appears to be small [15]. About 20% 
of patients have been reported to lose ER expression over time, explaining the lack of 
therapy response in these patients [45, 46]. Since tamoxifen response is associated to 
co-repressor recruitment, the overexpression of co-activators such as SRC-3 also 
called AIB1[47] and p/CIP[48], as well as downregulation of NCoR[49] and 
SMRT[48] have been coupled to resistance. ER is also activated by growth factors 
acting through the PI3K/AKT and MAPK pathway and directly interacting with AF-1 
in the N-terminal of ER [50, 51]. In addition, ER can also be activated through a variety 
of other proteins and post-translational modifications [52]. In addition to the nuclear 
role of ER its non-genomic effects are of interest as ER localized at the plasma 
membrane is suggested to interact with local proteins involved in signal transduction 
(Figure 1) [53].   
 
1.2.1.3 Cell cycle  
Various components of the cell cycle regulating system have been assigned a role in the 
resistance mechanism. Tamoxifen-resistant cells have been shown to manipulate the 
expression, activation and localization of positive regulators such as Cyclin D1 and 
Cyclin E1, and MYC [54, 55] and negative regulators such as p21, p27 as well as 
deactivation of the retinoblastoma protein (Rb) in order to circumvent the G1 arrest 
caused by tamoxifen [56, 57].   
   
1.2.1.4 Growth factor crosstalk 
Enhanced growth factor stimulation undermines the effectiveness of antiestrogen 
treatment.  Regular growth factor signaling includes receptor tyrosine kinase (RTK) 
dimerization upon ligand-binding followed by autophosphorylation, resulting in the 
activation of several signal transductions cascades e.g. the PI3K/AKT as well as the 
MAPK pathway. Various components of these pathways have been shown to support 
BC cells circumvent the inhibitory effects of tamoxifen by opting for alternate 
proliferation and survival signaling through bidirectional crosstalk with ER signaling. 
 
The best characterized mechanism involves the EGF family although insulin-like 
1(IGF1)-, fibroblast (FGF)- , and vascular endothelial (VEGF) growth factor also have 
been implicated in the crosstalk [45, 58]. Various molecular alterations enabling the 
overexpression of ligand or receptor HER2 have been associated with tamoxifen 
resistance [47, 59, 60]. Moreover, the overexpression of SRC-3, constitutively 
activation of PI3K, loss of the tumor suppressor PTEN, increased activation of AKT, 
ERK,  as well as p38, enhance signaling through HER2 and ER (Figure 1) [56, 60-63].  
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Figure 1. Simplified view of estrogen regulated pathways altered in tamoxifen resistance 
involving growth factor signaling. For details see text. Abbreviations: E2, estrogen; ER, 
estrogen receptor; EREs (estrogen responsive elements); CoA, co-activators; TFs, 
transcription factors; GFs, growth factors; RTKs, tyrosine kinase receptors.  
 
 
Although VEGF and its receptor VEGFR2 expression on endothelial cells and their 
function as regulators of angiogenesis is important for tumor cell growth, several 
studies have shown that BC cells per se express and secrete VEGF to a higher extent 
than surrounding normal tissue [64, 65]. As a consequence, increased signaling through 
the action of VEGF/VEGFR2 has been found to induce downstream ERK and PI3K 
most probably in an auto- or paracrine mode [66]. Moreover, HER2 is able to induce 
VEGF protein synthesis (Figure 1) [67].  
 
1.2.1.5 Other pathways 
The extensive research performed in this area has implicated various others players 
downstream of RTK signaling ultimately altering regulation of apoptosis, microRNA 
etc. Various components of an anti-apoptotic (BCL-2, BCL-XL) nature have been 
seen upregulated while pro-apoptotic (Bak, Bik, Caspase 9) are suppresed in 
tamoxifen-resistant models [45]. Recently, microRNAs in conjuction with HER2 have 
also been assigned a role in the resistance mechanism as reduced expression of miR-
221/222 and 342 as well as miR-451 were found to promote this state [68].  
 
The importance of the surrounding tissue of a tumor has been recognized and thus not 
to be forgotten in this context. Various proteins from the extracellular matrix such as 
integrins and fibroblast of tumor have showed a direct association to tamoxifen 
resistance [69, 70]. Moreover, epithelial mesenchymal transition-like (EMT) behavior 
in BC cells is induced by tamoxifen resistance involving Pin1 as an inducing factor [71, 
72]. 
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1.3 VASCULAR ENDOTHELIAL GROWTH FACTOR IMPLICATIONS IN 
BREAST CANCER 
VEGF exerts a major role in angiogenesis and plays a central role in local tumor 
growth and distant metastasis in BC [73, 74]. Increased VEGF expression and 
angiogenesis-related processes have been shown to be of adverse prognostic value in 
primary BC patients [75-77]. Moreover, increased VEGF expression correlated to 
poorer response in patients receiving adjuvant tamoxifen or chemotherapy [78, 79]. 
Interestingly, genetic polymorphisms in the VEGF gene have been associated to 
increased BC risk [80]. Having these facts in mind, the expectations were high for 
bevacizumab, a humanized antibody targeting VEGF, as it was implemented in the 
clinic. Although its use in combination with paclitaxel as first-line treatment of 
metastatic HER2 negative BC was approved by the Food and Drug administration 
(FDA) in 2008, the approval was revoked in 2010 due to poor benefit in relation to 
risks [81]. The obvious limitation is the lack of biomarkers predictive for 
antiangiogenic therapy. At present, various trials are investigating the potential of 
implementing bevacizumab to systemic adjuvant treatment. Even though other 
antiangiogenic agents are available none of them has been approved for clinical use so 
far [45].    
 
1.4 RETINOIC ACID RECEPTOR ALPHA 
 
Ever wondered why carrots are good for you? Well, carrots contain vitamin A which 
are metabolized into retinoids (mainly all-trans retinoid) (RA) generally known for 
being essential for the development of eyes but also skin, skeleton, and immunological 
function and stem cell differentiation [82, 83]. Once RA is in transported to the nucleus 
it signals through the interaction of retinoid acid receptors (RARs) and retinoid X 
receptors (RXR), in a similar way as ER [84]. Interestingly, RAR and RXR are 
believed to be dimerized in the absence of the ligand remaining transcriptional inactive 
by lowering their affinity to transcriptional co-activators while increasing it for co-
repressors such as N-CoR until ligand binding [85]. There are also reports suggesting 
the direction in which the receptor complex binds to the RA response element (RARE) 
on DNA is important for response to stimuli [86]. 
Retinoic Acid Receptor Alpha (RARA) is one of the three subtypes of RARs. There are 
many directly RARA-regulated genes involved in proliferation, apoptosis and 
differentiation. It is noteworthy that even genes lacking RAREs can be indirectly 
regulated by RA since many of its target genes include transcriptional regulators  [83].  
1.4.1 Signaling properties in cancer 
RAs have been show to act through various ways causing anti-proliferative, pro-
apoptotic and pro-differential effects in cancer cells [83]. The G1 arrest caused by RAs 
in order to block cell cycle progression is achieved by increased degradation and 
lowered expression of cyclins, cyclin dependent kinases (CDKs), growth inducers such 
as c-myc as well as co-activators inducing transcription of proliferative target genes 
[83, 87]. In addition, the inhibition of Rb phosphorylation pushes Rb to act as a tumor 
suppressor and cause a cell cycle arrest by inhibiting further transcription of cyclins 
[88, 89]. By increasing expression and stability of CKIs such as p21 and p27, RAs are 
able to suppress the role of CDKs in inducing the cell cycle [90]. However, the 
inhibitory effect on proliferation is believed to occur mainly through the action of the 
RAR  isoform [91].  
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The apoptotic effects of RAs are mainly caused by induction of RARA and have been 
observed in acute promyelocytic leukemia (APL) blasts, T lymphoblastic and myeloid 
leukemia, medulloblastoma, and melanoma cells. There are reports implicating TGF 
as an inducer of apoptosis in MCF7 cells [92]. However, apoptotic effects specifically 
implicating the RAR  have also been reported in BC cells [92]. 
 
Interestingly, the ability of RAs in inducing differentiation of various cancer cells into a 
less neoplastically transformed state has been of great interest in cancer research [83]. 
RA-induced differentiation is likely regulated by a complex transcription factor 
network involving FOX03A and Hoxa 1 [93, 94]. However, RA signaling is often 
altered in cancer due to epigenetic alterations compromising expression of RARs or 
transcriptional regulators [92]. In addition, the PI3K/AKT pathway has also been 
shown to have an inhibitory effect on RAR  expression [95].  
 
Recently, the interaction between RA and E2 signaling was revealed as it was shown 
that RARA and ER not only share a large number of DNA binding regions in MCF7 
cells but also that the nature of the interplay is antagonistic [96]. The authors also 
showed that the transcription factor FoxA1 is required for RARA recruitment to 
specific target sites [96]. However, contradictory results presented evidence of a co-
operative signaling between RARA and ER suggesting that ER is dependent on RARA 
and that RARA is able to interact with ER binding sites in an E2-dependent manner 
[97]. 
1.4.2 Retinoids in cancer therapy 
Based on all the reported effects on cancer cells RAs were introduced to the treatment 
of various types of cancer. Although the effects are known, the exact mechanisms used 
by RAs to achieve these are still not fully elucidated. APL has been successfully treated 
with all-trans RA (ATRA) in combination with arsenic trioxide as it induces 
differentiation of cells and degrades the fusion protein PML/RARA, which is expressed 
by most part of APL patients [98]. RAs are also employed in the treatment of lymphoid 
malignancies, basal cell skin cancer [99, 100]. The use of RAs in solid tumors has been 
limited due to lack of significant effect. A recent metaanalysis including 248 studies 
evaluating RAs in lung cancer therapy and prevention concluded that bexarotene may 
be a promising agent. Notably, a large study presented indications of an increased risk 
of lung cancer in relation to bexarotene [101]. In BC, fenretinide has been suggested as 
a preventive agent for second primary BC in premenopausal women in combination 
with tamoxifen and is currently being studied further. However, preliminary results 
show no benefit of the combined treatment [102, 103].  
 
1.5 PROTEOMICS 
The word proteome was coined by Marc Wilkins in the 90’s as a corresponding term 
for the genome, but as the name implies, referring to the entire set of proteins expressed 
by the genome in a certain cell at a specific time. Proteomics encompasses the studies 
of the proteome. Basically most peptide sequences of six amino acids or more are 
unique for a single gene product meaning that if their sequence is obtained the 
corresponding proteins can be identified. The development of technologies within 
proteomics has resulted in today’s robust and reliable high throughput methods based 
on mass spectrometry (MS), capable of identifying and quantifying number of protein 
simultaneously, and protein array technologies as opposed to classic protein detection 
methods such as immunoblotting limited to studying only one protein at a time. MS has 
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also shown superiority in accuracy when measuring molecular weights compared to 
sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) [104]. 
Proteomics has developed tremendously fast and thanks to the integration and tuning of 
other tools besides MS, such as protein and peptide separation methods, it is receiving 
acknowledgement from the research community. It is exciting times seeing the field of 
proteomics evolve continuously aiming towards improved resolution, sensitivity and 
accuracy of protein identification and quantification.      
1.5.1 Top-down versus bottom-up proteomics 
 
In general, proteomics methods differ in the choice of studying either proteins 
themselves or peptides, the fragments of proteins. Top-down proteomics is an approach 
that studies proteins since identification and quantification occurs prior to digestion of 
proteins into peptides. In the present work we chose to do bottom-up proteomics which 
puts the digestion as the first step in the workflow. Although there are advantages and 
disadvantages with each approach we, in our group, focus on the optimization of 
bottom up proteomics. We consider this approach to be the most advantageous in 
identification efficacy, proteome coverture, and quantification accuracy.  
 
The most commonly used protein separation method in top down proteomics is 2 
dimensional (2D) SDS-PAGE. This technique separates proteins by their isoelectric 
point and size. As a result a snapshot of the most abundant proteins present in the 
sample is obtained. Staining of the gel enables the identification and quantification of 
the proteins of interest. These are consequently excised and digested prior to MS 
analysis [104, 105].  
 
Although some researchers advocated the top-down approach, the bottom-up approach 
is the most widely used choice. The benefit of 2D gel separation is the visualization of 
proteins although not optimal for small, poorly soluble or low abundant proteins. There 
is also the issue of poor reproducibility. Another advantage of working with peptides as 
in bottom-up proteomics is that the complexity of samples can be reduced more easily. 
In addition, peptides are more suitable for MS analyses compared to proteins.       
1.5.2 Methodological pipeline 
The workflow in bottom-up proteomics integrates various components each with a 
specific task required for optimal results. It all starts with choosing the most optimal 
starting material and preparing the samples making them compatible to the analyzing 
purposes. The fractionation of a sample according to localization or characteristics of 
protein types is an approach allowing for a more targeted analysis and can also be of 
help with the interpretation of the final data. The main characteristic of the bottom-up 
approach is the upfront digestion of proteins in the samples into small peptides. This is 
usually done by using the enzyme trypsin which cleaves only after the amino acids 
arginine or lysine. Samples are labeled with isotope-containing tags called iTRAQ 
allowing quantification and thereafter fractionated. The samples are then inserted into 
the MS instrument where the proteins are identified through peptide sequencing and 
quantified by estimation of intensities of the reporter ions formed from iTRAQ. By 
applying advanced biostatistics and using appropriate software, the extensive list of 
identified proteins is processed narrowing the detected targets down to a manageable 
size as it is put into biological context (Figure 2). 
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Figure 2. Overview of the experimental workflow followed by functional analysis and 
ultimately validation in patient samples. For details of the workflow see text. Abbreviations: 
WB, western blot; TMA, tissue micro array; IHC, immunohistochemistry.   
 
 
1.5.2.1 iTRAQ labeling 
Our group performs quantitative proteomic analyses in order to be able to compare 
proteome changes caused by perturbations such as treatment or biological differences. 
This is done by using up to eight stable isobaric tags for relative and absolute 
quantification, called iTRAQ, which consist of a charged reporter group, a peptide 
reactive group and a neutral balance portion balancing all eight tags in mass. Following 
protein digestion, the peptide mixture is labeled with these tags which bind covalently 
to primary amine groups, and all eight samples are consequently pooled. Each tag 
exhibits a different fragmentation pattern by MS/MS giving rise to unique reporter ions 
thus enabling the relative quantification of each labelled peptide [106]. 
 
1.5.2.2 Fractionation 
One of the most problematic issues in proteomics has been to deal with the complexity 
of samples. Therefore the aim has been to optimize and simplify samples before the 
quantification and identification of peptides. It is believed that by reducing the 
influence of peptides from high abundant proteins the discovery of less abundant and 
perhaps more interesting proteins will be facilitated. Samples are therefore subjected to 
immobilized pH gradient-isoelectric focussing (IPG-IEF). This approach uses the 
difference in isoelectric point of peptides within a specific range of pH to separate 
them. Although the narrow range IPG-IEF applied from pH 3.5-4.5 only captures a 
subset of peptides they still exhibit high representation of all present proteins. This is 
justified by in silico data strongly suggesting that 96% of all proteins have at least a 
corresponding peptide within this range [107]. 
 
 20 
1.5.2.3 MS-based protein identification (tandem MS) 
The next step in the workflow includes mass spectrometry, a method used for the 
identification of peptides. Before we get lost in translation a short description of the 
basic principle of MS is required. MS is used to measure the mass of peptides by first 
ionizing the molecules and then determining their mass to charge ratio. A sample has to 
travel through 3 key compartments in the mass spectrometer, the ion source, mass 
analyzer and detector. First, the sample is vaporized for ionization of molecules. 
Secondly, these ions are equally accelerated into a focused beam where the velocity of 
each ion depends on the mass to charge ratio. The ions are consequently guided to the 
compartment where mass separation and analysis is performed by using different 
methods depending on the MS-instrument of choice. The output is represented as a 
famous stick diagram or mass spectrum, showing ion intensity on the y-axis and the 
mass to charge ratio (m/z) on the x-axis [104]. 
 
In the current work we used two ionization methods called matrix assisted laser 
desorption ionization (MALDI) and electro spray ionization (ESI). As the name 
implies, the ionization in MALDI is performed by a laser in cooperation with the 
matrix which the sample was mixed onto [104]. ESI is based on the release of gas-
phase ion-like molecules as the density charge on the surface of sample droplets 
becomes too much and tears the droplets open. Moreover, ESI is better at keeping 
molecule fragmentation at a minimum [108].   
 
  Next is a brief introduction to the mass analyzers, time of flight (TOF)-TOF, also 
known as MS/MS, quadrupole (Q)-TOF and linear ion trap quadrupole (LTQ)-
Orbitrap, used in this work. When using TOF the determination of the mass to charge 
ratio is based on the time it takes for the accelerated ions to reach the detector in a 
vacuum free flight zone of the TOF analyzer as lighter ions travel at a higher speed and 
vice versa. The extra TOF is actually not a spelling mistake but the addition of such a 
component. It is responsible for analyzing the mass of fragments of peptides selected 
for fragmentation after the first mass analysis single MS-spectra. The merging of the 
precursor mass from MS and the fragmentation masses from MS/MS results in the 
determination of the amino acid sequence of a peptide by comparison of the 
experimental data to theoretical database. Q-TOF and ion trap both use a quadrupole as 
mass analyzer. The quadrupole consists of four metal rods arranged in parallel through 
which selected ionized molecules pass driven by the magnetic field within this rods. 
LTQ differs from the regular quadrupole as it analysis ions in a pulse mode as opposed 
to a continuous flow, by capturing them in an ion trap of extended volume by additional 
repulsive rods in the ends of the quadrupole rods [109]. The LTQ-Orbitrap is a mass 
analyzer representing the combination of two techniques which complement one 
another. The orbitrap uses an electrostatic field to separate the masses instead of a 
magnetic [28].  
 
As a last step, a mass spectrum is obtained by the detector as it detects the masses and 
number of ions that reaches it. Once we have obtained the spectra with peptide 
fragments the job of identifying the corresponding protein begins. A database search 
algorithm (i.e. MASCOT, paragon) is used to match the experimental fragments to in 
silico generated ones in order to identify the peptide. Several commonly used existing 
sequence databases and various software are employed resulting in a very extensive list 
of identified proteins.     
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1.5.2.4 Tools for biological interpretation  
The next step of putting all this data into context is complicated. Fortunately the quality 
of software developed to facilitate this analysis, is continuously improving. Despite 
this, reliability and coverage of databases are some of the issues that still have to be 
taken under account. The role of systems biology, which integrates computational, 
biological and medical input, is invaluable since it simplifies the handling of data 
severely [110]. Software, such as SIMCA, Ingenuity Pathway Analysis (IPA), Gorilla, 
Proteincenter (Proxeon) etc., were employed in paper III and IV. SIMCA is a program 
suitable for performing multivariate data analysis. The other mentioned programs use 
biological and medical knowledge to define protein characteristics and relationships 
between them. 
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2 AIMS OF THIS THESIS 
The overall aim was to identify potential markers for tamoxifen resistance by merging 
knowledge from a cell model system and human tumors. 
 
 
The specific aims of each paper were:   
 
 
I. To investigate if VEGF/ VEGFR2 signaling implicating p38 MAPK is involved in 
the molecular mechanisms of tamoxifen resistance. 
 
II. To validate the importance of VEGF expression on survival after adjuvant 
tamoxifen treatment and to explore a possible relation between VEGF levels and 
treatment duration. 
 
III. To explore the proteomic profile of MCF7 BC cells and the 4-hydroxytamoxifen-
resistant MCF7/LCC2 subline by using mass spectrometry-based proteomics in search 
of key differences involved with the resistance mechanisms. 
 
IV. To discover potential predictive biomarkers for tamoxifen response by using mass 
spectrometry-based proteomics on tumor samples from primary BC patients.     
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3 MATERIAL 
3.1 CELL LINES 
The cell model of choice was MCF7 and its subline called MCF7/LCC2 (referred to as 
LCC2). The parental cell is the most commonly used in breast cancer research 
originating from a pleural effusion from a 69-year old BC female patient diagnosed 
with invasive ductal carcinoma [111]. LCC2 is a 4-OHT-resistant cell line derived from 
a series of sublines originating from MCF7. MCF7/MIII was the first cell line derived 
from MCF7 having obtained a hormone-independence for growth in vitro and in vivo 
as opposed to parental cells. Further selection of these resulted in the acquisition of 
MCF7/LCC1, a subline with a more malignant phenotype despite no apparent 
differences in genomic amplification compared to MCF7 [112]. Although MCF7/MIII 
and MCF7/LCC1 can form tumors in mice without supplemental E2 their growth is 
still induced by E2. LCC2 cells are the result of the exposure to stepwise increasing 
concentrations of 4-OHT, the main metabolite of tamoxifen, of MCF7/LCC1 cells until 
becoming resistant. They were defined resistant when 1µM of 4-OHT only caused a 
decrease in proliferation by 15%. An additional trait by the resistant cell line was the 
hormone-independence when growing both in vitro and in vivo while maintaining ER 
levels similar to that of MCF7 cells [113]. 
 
3.1.1.1 Reflecting on the choice of cell model  
We opted for these cell lines since we considered them representative of a reliable 
model which could mirror the biological process of acquired tamoxifen resistance. The 
main characteristics that make LCC2 cells a useful model for studying resistance 
mechanisms is their ability to maintain similar levels of ER expression as the parental 
cells while sustaining tumorigenic ability to induce tumor growth without the need of 
hormone supplementation. Moreover, the proliferation of LCC2 cells is not induced by 
tamoxifen as opposed to several other tamoxifen resistant cell lines [114, 115].  
 
Although cell lines may seem like the optimal tool due to their endless growth 
potential, we have to be aware of the limitations that come with them. Cells are 
relatively easy to take care of except that they may undergo phenotypic or genotypic 
changes during culturing. These changes can occur due to a variety of reasons such as 
altered temperature, carbon dioxide levels and oxygen, continuous exposure to trypsin 
and contamination with mycoplasma, viruses or even other cell types [111, 116]. 
However, it is important not to forget that cell models are great tools for research and 
that by taking the required precautions problems can be overcome to a certain degree. 
This is the reason till why we, in our lab, maintain all our cells under the same 
conditions using each stock of cells for up to a maximum of two months. In order to 
avoid contamination only mycoplasma-negative cells are allowed into the culture room 
and freezer storage.   
3.2 PATIENTS 
In general, patients from both cohorts received similar primary treatment according to 
standard guidelines. All patients underwent standardized breast conserving surgery 
followed by radiotherapy. Dissection of axillary lymph nodes was performed in eligible 
patients excluding those of high age or with concomitant diseases. It is important to 
mention that patients were randomized into two arms as part of a phase III clinical trial 
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studying two vs. five years of adjuvant tamoxifen until 1995 as the 5-year regimen 
became standard therapy. After primary treatment the patients were observed for a long 
period of time by annual clinical examinations and mammograms at their 
corresponding clinics. Survival times were calculated as the time from diagnosis to the 
date of first recurrence or death, and for relapse-free patients to last clinical 
examination. Recurrences were defined as the first documented evidence of new 
disease manifestations in the loco-regional area, contralateral breast, in distant sites or a 
combination of those. The REMARK criteria were taken into account during selection 
of both patient cohorts. 
3.2.1 Cohort I 
Data on a total of 711 frozen tumor homogenates with a known hormone receptor 
status from patients diagnosed with primary operable BC from 1991 to 1996 was made 
available to us from the Breast Cancer database at the Regional Oncologic Centre, 
Linköping University Hospital, Linköping, Sweden. This database contains information 
on all patients from the Southeast Sweden Health Care Region with primary BC. The 
clinical data obtained from this database included: Age, gender, tumor size, steroid 
receptor status, node status and S-phase fraction.  For the purpose of studying the sole 
effects of tamoxifen we included 402 out of 449 eligible patients with ER positive BC 
of stages I–III having received tamoxifen as the only adjuvant therapy. Patients with 
locally advanced BC, displaying distant metastases at diagnosis, or having received 
neoadjuvant therapy, were excluded. A description of the patients’ characteristics is 
listed in Table 2. Data on nodal status were limited to 96% of the patients. The median 
follow- up time in relapse-free patients was 9.8 years. The study design was approved 
by the research ethics board of Linköping University, Sweden. Apart from the analyses 
we performed on this patient material in the present work we had access to data on 
previous measurements done by our group on levels of p38, JNK and ERK.  
 Paper II 
 Four hundred and four patients were included in this study. 402 samples 
 were included since 47 were unavailable due to sample limitation. 
 Paper III 
 Eight random matched samples from a total of the twenty four samples 
 used in paper IV were used for the verification of MS data by western 
 blot. 382 patients were included for the validation of functional studies by 
 enzyme-linked immunosorbent assay. We were unable to analyze 67 
 samples from the original cohort due to limitations of tumor homogenate 
 availability.  
 Paper IV 
 24 samples were included in this pilot study. Twelve patients 
 relapsing within two years were matched to patients remaining 
 relapse-free for more than seven years according to age, tumor size and 
 nodal status.  
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Feature 
Cohort 1 
Nr of patients 
Cohort 1 
Nr of patients 
Patients enrolled 402 45 
Tumor size, mm 
Median (range) 
 
20 (3-150) 
 
15 (6-50) 
Stage 
T1 
T2-T3 
 
222 (55) 
180 (45) 
 
32 (71) 
13 (29) 
S-phase 
<10% 
>10% 
Unknown 
 
267 (66) 
94 (23) 
41 (11) 
 
NA 
NA 
NA 
Lymph node status 
Node-negative 
Node-positive 
Unknown 
 
200 (50) 
184 (46) 
18 (4) 
 
32 (71) 
10 (22) 
3 (7) 
Histopathological grade 
I-II 
III 
Unknown 
 
NA 
NA 
NA 
 
22 (49) 
19 (42) 
4 (9) 
ER 
Median 
Pos (>0.05 fmol/µg DNA) 
Neg (<0.05 fmol/µg DNA) 
 
NA 
402 (100) 
0 
 
1.93 (0.0 10.4) 
8 (18) 
37 (82) 
PR 
Median (range) 
Pos (>0.05 fmol/µg DNA) 
Neg (<0.05 fmol/µg DNA) 
Unknown 
 
3.0 (0-36.0) 
357 (89) 
45 (11) 
 
 
1.45 (0-10.6) 
13 (29) 
31 (69) 
1 (2) 
HER2 
Pos 
Neg 
 
NA 
NA 
 
4 (9) 
41 (91) 
VEGF, pg/µg DNA 
Median (range) 
Low 
high 
 
2.4 (0-85.3) 
201 (50) 
201 (50) 
 
2.3 (0-320.9) 
21 (47) 
24 (53) 
Tamoxifen therapy 
2 years 
5 years 
 
149 (37) 
253 (63) 
 
27 (60) 
18 (40) 
 
Table 2. Summarizing table of tumor characteristics of the two cohorts included in this thesis. 
 
3.2.2 Cohort II 
The original cohort included 679 patients diagnosed with primary operable invasive BC 
at the Karolinska University Hospital and St Görans Hospital, Stockholm during 
January 1993 to December 1996. Clinical data for these patients included: Age, gender, 
tumor size, steroid receptor status, grade, node status and HER2 status (Table 2). 404 
patients of these received adjuvant endocrine therapy up to five years out of which 295 
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had a BC positive for both ER and PR. Within the TMA used in paper III, there were 
95 available tumor tissues of which 45 were evaluable by immunohistochemistry. The 
median follow-up time in recurrence free patients was 11.2 years. Detailed 
characteristics of patients included in the TMA are included in the third manuscript. 
The medical ethical committee of the Karolinska Institute, Stockholm, Sweden, 
approved the study design. Data on previous measurements of JNK and ERK on TMAs 
and VEGF, VEGFR2 and p38 on tumor homogenates from this cohort was available to 
us.   
 
3.2.2.1 Reflecting on patient cohorts 
When considering material for biomarker discovery or validation it is important that the 
handling and preparation of samples follows an approved standard protocol and is 
instantaneous from the moment it is collected from the patient [117]. This should be 
done in order to avoid decomposition or degradation of analytes of interest. Moreover, 
if all samples are prepared equally it sets an assumptive baseline for all samples. 
Therefore, the preparation of our samples followed a strict standardized operating 
procedure handled by experienced technicians as these samples were used for 
determination of ER and PR within clinical routine. As a matter of fact, both 
Linköping, as well as Karolinska University Hospital participated in the external 
quality assessment program arranged by the EORTC- Receptor and Biomarker Group 
at the Quality Assessment Laboratory, University Medical Centre Nijmegen, 
Netherlands. 
 
Since a representative piece of the tumor was collected there is the issue of tumor 
heterogeneity to be considered. It is possible that the collected specimen not only 
consists of tumor cells but also stromal and other infiltrating cells making in difficult to 
decide the true origin of the analytes of interest. Considering the scarcity of tissue 
material it is noteworthy that tumor homogenates were adequate material for our 
purposes and were ample allowing measurements of various proteins. The strengths of 
our more extensive patient material (cohort I) are many including the homogeneity, the 
relatively long follow-up and the extensive and informative clinical data. One drawback 
could be that we did not limit ourselves to include randomized patients only in our 
studies. Moreover, we are aware that cohort II was too small to achieve any statistical 
power or significance. We included this cohort as a test material for another platform, 
the histological one, since it remains the standard platform for new biomarkers aiming 
to be included in post surgical routine analysis for primary BC.  With these drawbacks 
in mind, we consider our data to be more of a hypothesis-generating character. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-
hydroxytamoxifen in MCF7 breast cancer cells 
This study was initiated by our previous observations describing an association 
between high VEGF, VEGFR2 and positive p38 expression and early recurrences in 
ER positive patients during adjuvant tamoxifen treatment [118]. These results 
suggested involvement of these factors in the mechanism of tamoxifen resistance. In 
order to study this closer we turned to a cell model system consisting of two cell lines 
with different responsiveness to 4-hydroxytamoxifen (4-OHT), the active metabolite of 
tamoxifen, LCC2 and the parental sensitive MCF7 cell line [113]. We hypothesized 
that in 4-OHT-resistant LCC2 cells p38 could partly be activated as a consequence of 
increased VEGF/VEGFR2 signaling enabling them to proliferate even in the presence 
of 4-OHT.  
 
Cells were exposed to 4-OHT to confirm their different responsiveness to the treatment 
by analyzing their viability. The most noticeable differences between cell lines were 
found six days post treatment defining the default time point for this study. 
Interestingly, in comparison to MCF7 cells, untreated LCC2 cells secreted higher levels 
of VEGF and although the secretion decreased in a dose-dependent manner, VEGF 
levels remained higher than in MCF7 cells. As for VEGFR2 expression, despite similar 
basal levels in both cell lines the proportion of activated receptor was higher in LCC2 
cells. In response to increasing concentrations of 4-OHT, the expression of VEGFR2 in 
LCC2 cells remained intact while activated levels were somewhat lowered although 
still higher than in sensitive cells. 
  
Moreover, basal p38 expression was also higher in LCC2 cells with an increasing 
tendency in response to 4-OHT. Interestingly, the treatment affected the 
phosphorylation pattern of p38 in these cell lines differently. The activity of p38 was 
affected in a dose-dependent way, increasing in MCF7 while decreasing in LCC2 cells 
arguing for potential difference in antibody specificity between the activated and total 
p38. 
 
 There are four different isoforms of p38 where  and  have been mostly studied and 
found to be of pro-apoptotic and proliferative nature, respectively. Since they appear to 
regulate each other the dominating one will consequently influence which pathway 
becomes activated [119]. We speculate that the overexpressed and thus dominating 
isoform, inducing the activation of proliferative pathways in LCC2 cells, may be p38 
by inhibiting the activation of p38and thereby also blocking its own degradation 
(Figure 3). Appropriately, recent studies assigned p38 a critical role in maintaining 
oncogenic properties and contributing to resistance to DNA damage in BC cells [120].   
 
We also studied the role of p38 in viability by pre-exposing the cells to a 
pharmacological inhibitor called SB202190 followed by co-treatment with 4-OHT. The 
remarkable effect of the inhibitor per se led us to the conclusion that inhibition of p38 
gave an additive effect to that of 4-OHT treatment on cell viability in both cell lines. 
 We proceeded by silencing VEGF or VEGFR2 expression in LCC2 cells with the 
intent to pinpoint if VEGF indeed was signaling through VEGFR2 and whether or not 
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p38 was involved in this pathway. VEGF silencing decreased the expression of both 
total and phosphorylated VEGFR2 and p38 although the latter did not decrease to the 
same extent. Moreover, when VEGFR2 expression was repressed a reduction of total 
and phosphorylated p38 was seen. However, VEGF was only slightly reduced. 
 
 In conclusion, our results from this paper suggest that the existence of an autocrine 
release and action of VEGF through VEGFR2 involving p38 is characteristic for 4-
OHT-resistant BC cells. 
 
Increased VEGF secretion has also been reported in TAMR-MCF7 cells, a similar type 
of 4-OHT-resistant MCF7 cells. Moreover, these cells form tumors with high 
angiogenic intensity regulated by Pin1 through activation of c-Jun [121]. Pin1 proved 
to be, implicated in the induction of an EMT-like state in TAMR-MCF7 cells, and 
regulated by the activation of E2F1/pRb, a key regulator for cell cycle progression, 
whose activation is in turn dependent on PI3K and p38 (Figure 3). Importantly, 
inhibition of p38 decreased VEGF secretion in the resistant cells [121, 122]. Additional 
functions assigned to p38 include both stabilization of VEGF mRNA and 
phosphorylation of ER (Figure 3) [123]. p38 is likely to have a wide influence in 
tamoxifen resistance thus explaining the significantly reduced viability of the LCC2 
cells when inhibiting p38. 
 
This data strengthens our theory about the autocrine loop active in tamoxifen-resistant 
cells involving VEGF/VEGFR2 and p38. However, although it is tempting to claim 
that VEGF/VEGFR2 signaling works as a collaborating pathway with HER2/PI3K 
signaling, as suggested by others [63, 67], MCF7 cells are HER2 negative and thus 
such statement cannot be applied in our model system [124].  
 
Unfortunately, the effect of bevacizumab has not been consistently successful in BC 
therapy. There is, however, a possibility that the lack of effect is due to a diluted 
response as a consequence of not identifying the patients that would benefit the most. 
Considering our findings, perhaps a combination of Bevacizumab plus tamoxifen could 
increase response in patients exhibiting high levels of VEGF? Importantly, completed 
phase II trials investigating feasibility and effect of combined endocrine therapy plus 
bevacizumab have reported beneficial effects apart from recurrent side-effects [125, 
126]. Similar randomized phase III trials are currently ongoing and thus the effect of 
bevacizumab in this setting remains to be seen. 
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4.2 PAPER II 
Prolonged tamoxifen increases relapse-free survival for patients with primary breast 
cancer expressing high levels of VEGF 
 
Earlier studies have shown that high VEGF levels in primary breast tumors correlate to 
shorter survival times for patients treated with adjuvant tamoxifen [127-130]. With this 
study we aimed to validate the potential adverse prognostic effect of VEGF. The 
expression of VEGF was determined, in the cytosolic fraction of tumor homogenates 
from 402 patients with an ER positive BC receiving tamoxifen as adjuvant therapy, by 
using enzyme linked immunoassays. As the majority of these patients (253/402) had 
received tamoxifen for five years while the rest were treated for two years, we also 
intended to evaluate the impact of treatment duration on survival taking expression of 
VEGF under consideration. 
 
Statistical analyses were performed looking to validate the previously reported adverse 
prognostic value of VEGF in tamoxifen treatment. Moreover, associations between 
VEGF expression and survival were of interest to emphasize the importance of 
tamoxifen treatment duration.  
 
Our results did indeed confirm the adverse prognostic value of VEGF expression in 
patients receiving tamoxifen. Moreover, when studying the cohort by treatment 
duration, no significant difference in outcome was observed between high vs. low 
VEGF-expressing patients in the 5-year regimen. There was, however, a significant 
decrease in survival for patients with high VEGF expression among those receiving 
tamoxifen for two years. In other words, high VEGF expression does not influence the 
outcome provided patients receive a prolonged tamoxifen treatment. 
 
In addition, supporting evidence from a large randomized trial showed that the negative 
prognostic impact of peritumoral vascular invasion (PVI), which correlates with VEGF 
levels, was not seen in steroid receptor positive BC patients when receiving five years 
of tamoxifen [77]. 
 
When patients were separated and analyzed according to VEGF expression, the 5-year 
regimen proved to be more beneficial in the high VEGF-expressing patients.  
Interestingly, the positive effect of the prolonged tamoxifen regimen on survival was 
not seen in the subset of patients exhibiting low VEGF levels. These results imply that 
the duration of treatment does not influence the outcome of patients as long as they 
express VEGF at low levels.  
 
The consensus on tamoxifen treatment duration for postmenopausal women has been of 
five years after presented evidence of a significant benefit in comparison to two years 
of tamoxifen [131]. Our results point at no benefit gain with the prolonged regimen if 
patients do not express VEGF at a higher extent. Interestingly, the latest 
recommendations regarding endocrine treatment in postmenopausal patients are that 
AIs should be used either upfront or after tamoxifen treatment for a maximum of five 
years or as an extension to five years of tamoxifen [36]. This includes often combining 
treatment in a sequential manner such as three years of tamoxifen plus two years of AI 
or the opposite starting with an AI upfront. Our results suggest that patients expressing 
high levels of VEGF would specifically benefit from an extended tamoxifen treament 
followed by an AI rather than only three years of tamoxifen.  
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Although there are studies suggesting that treatment with AIs may be more beneficial 
than tamoxifen in patients expressing high VEGF levels, no such correlation has been 
observed [132].  Recently the combination of an AI and bevacizumab for the treatment 
of postmenopausal women with metastatic BC has shown promising effects and is still 
being evaluated [125, 126]. However, no trials evaluating tamoxifen or comparing both 
endocrine treatments in such setting have been performed.   
 
It is important to keep in mind the possibility of an interaction between VEGF and 
HER2 considering the evidence presented by preclinical [63, 67] and clinical studies 
[133, 134] showing the existence of such a relationship. 
 
In summary, high VEGF was significantly correlated to an impaired survival after 
adjuvant tamoxifen treatment in the whole patient population. However, an improved 
survival was observed in patients with high VEGF-expressing tumors provided they 
were given tamoxifen for a prolonged time period.   
  
  
   31 
4.3 PAPER III 
 
Deregulated retinoic acid receptor alpha signaling in tamoxifen resistance is of 
potential predictive value in steroid receptor positive breast cancer 
 
Having concluded that 4-OHT-resistant LCC2 cells may have a VEGF/VEGFR2- 
driven autocrine loop involving p38 in paper I, we decided to continue exploring the 
characteristics of each of these two cell lines, however, this time with a high throughput 
methodology. Our aim was to do an unbiased discovery of potential key players in 
tamoxifen resistance by performing quantitative MS-based proteomics on MCF7 and  
LCC2 cells, prior and post exposure to 4-OHT.   
 
We used a bottom-up proteomics approach for this purpose. The samples of origin were 
lysates from cells treated with 4-OHT for three days and corresponding untreated cells. 
In order to study the non-genomic and genomic effects of altered ER signaling 
associated with tamoxifen resistance, lysates were fractionated and analyzed separately 
as two subcellular fractions, a DNA-binding (nuclear) and a cytosolic. 
In short, samples were consequently digested, labeled with iTRAQ and additionally 
fractionated by IPG-IEF. Next, they were analyzed by nLC-MALDI-TOF/TOF and 
nLC-Q-TOF where proteins were identified through peptide sequencing and quantified 
by estimation of intensities of the reporter ions formed from iTRAQ. By using in-house 
software, denoted PQPQ [135], quantitative accuracy was enhanced by removing 
outliers and thus quantification of biological replicates was enabled. We identified a 
total of 830 proteins of which 201 and 629 were found in the nuclear and cytosolic 
fraction, respectively.  
The extensive list of identified proteins was processed using advanced biostatistics to 
include only significantly deregulated proteins. In general, the three top cellular 
functions in which the most significantly deregulated proteins where involved in were 
cell cycle, growth and cell to cell signaling when comparing untreated LCC2 to MCF7 
cells. In response to 4-OHT, the most relevant functions of proteins included cellular 
assembly, morphology and proliferation in MCF7 cells while LCC2 cells appeared to 
circumvent the effect of 4-OHT by deregulating proteins involved in cell death, cellular 
compromise and cell cycle. 
Consequently, pathway analyses revealed a connection between RARA and 
significantly deregulated proteins in the proteomics data set. RARA is normally 
involved in anti-proliferative signaling inducing apoptosis and differentiation. Recent 
work by Hua et al, showed an antagonistic interaction between ER and RARA 
signaling [96]. However, these two pathways were later reported to co-operate with 
each other [97]. When displaying proteins shown to be regulated by ER and RA [96, 
136] separately within each fraction, the RA-regulated ones seemed to be the most 
abundant in our data set. This raised our interest in RARA and we proceeded by 
functionally exploring it in the cell model system.   
 
RARA expression was similar at basal levels in both LCC2 and MCF7, increasing only 
in MCF7 after 4-OHT treatment. Moreover, exposure to the RARA agonist, AM580, 
resulted in G1 cell cycle arrest in MCF7 cells similarly to the effect of 4-OHT. In 
contrast, LCC2 cells remained more or less unaffected by either treatment. When 
analyzing viability, the antigrowth response caused by AM580 was decreased in LCC2 
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compared to MCF7 cells. Furthermore, depletion of RARA by siRNA increased 
viability in MCF7 while significantly decreasing viability in LCC2 cells.  
 
RARA seems to act as a brake repressing the growth properties in MCF7 cells. In the 
absence of a brake the repressive growth regulation is decreased allowing cells to 
proliferate. However, RARA seems to exert a different function in LCC2 cells. RARA, 
supported by an altered environment seems to be of importance for sustaining viability 
of LCC2 cells.  
 
Interestingly, RARA expression was shown to be upregulated in patients with early 
relapses (<2 years) compared to relapse-free patients (>7 years of relapse-free follow-
up). We hypothesize that patients with early relapse may have acquired a switch in 
RARA signaling together with other co-regulators allowing increased levels of RARA 
to promote proliferation in the presence of tamoxifen.  
 
A primary validation on tumor homogenates from 382 ER positive patients receiving 
adjuvant tamoxifen for two or five years showed a significant correlation between high 
RARA expression and shorter RFS in patients treated with the 2-year regimen (n=63) 
(p=0.0028). Analysis of RARA by IHC, in a second independent cohort of 45 patients, 
showed the same tendency in respect to RFS, although did not achieve statistical 
significance.  
 
An issue to take under account is that RARA expression in the samples analyzed by 
IHC does not seem to correlate with HER2 status. The close proximity of the RARA 
gene to the HER2 amplicon [137] raises the question whether or not there is a relation 
between these two factors. Since HER2 status is unknown in the main validating cohort 
it is an issue to be pursued. Moreover, RA in combination with tamoxifen has been 
suggested to be of benefit in HER2-overexpressing, ER positive BT474 BC cells [138]. 
This connects HER2 with a regular anti-proliferative RARA signaling in contrast to 
RARA’s role in high VEGF/VEGFR2-expressing cells, such as LCC2.  
 
Since VEGF is a RA-regulated gene, we also analyzed the effect of RARA modulation 
on VEGF in both cell lines and found that VEGF was regulated differently between cell 
lines. Interestingly, VEGF secretion in LCC2 cells was increased by both induction and 
silencing of RARA suggesting that RARA is only partly involved in the overexpression 
of VEGF seen in the 4-OHT-resistant cells. Interestingly, a strong correlation was seen 
between RARA and VEGF expression (p<0.0001) in the main validating cohort.  
 
RARA is controlled by multiple actors interacting with one another in a complex 
manner and thus resulting in the integration of various pathways of the molecular 
machinery.  The transcriptional activity of RARA is modulated by phosphorylation of 
co-activators, such as SRC-3, and co-repressors. Apart from this, RARA is believed to 
exert non-genomic functions implicating the direct interaction with SRC-3 as a 
consequence of RA-induced activation of SRC-3 through p38 [139]. RARA can also be 
activated in a ligand-independent manner, for instance, in response to growth factors or 
through direct interaction with MAPKs. Speculating on possible associations to our 
findings in paper I, it is tempting to say that the possibility that RARA is part of the 
autocrine loop involving VEGF/VEGFR2 and p38 in LCC2 cells exists.   
 
RARA has been also been shown to directly interact with Pin1, a protein shown to 
induce EMT-like behavior and tumor angiogenesis involving p38 and VEGF in BC 
cells [72, 121, 122]. However, Pin1 induces degradation of RARA unless a mutation on 
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a specific phosphorylation site on RARA is present [140, 141]. Therefore, inhibition of 
Pin1 results in increased RARA levels and as a consequence also improved response to 
RA treatment in acute myeloid leukemia (AML) [140]. In LCC2 cells, however, the 
role of RARA appears to be different, promoting survival of cells to a certain extent. 
Whether or not RARA, in LCC2 cells, contains the mutation that abolishes Pin1’s 
ability to degrade RARA and instead is activated by their interaction, remains to be 
explored (Figure. 3). 
   
In conclusion, we show that the function of RARA is deregulated in LCC2 cells in 
comparison to MCF7. LCC2 is dependent on the presence of RARA to sustain viability 
in contrast to MCF7 cells, suggesting that high expression of RARA in tumors from 
early relapse patients supports proliferation of these tumors. Also, RARA is suggested 
to be of potential prognostic and predictive value in ER positive BC patients. 
 
 
 
 
 
 
Figure 3. Illustration summarizing hypothetical implications of our findings based on related 
published observations. The potential role of p38 in the autocrine loop present in LCC2 cells 
(blue arrows). Potential implications of an altered RARA signaling in tamoxifen resistance (red 
arows).   
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4.4 PAPER IV  
 
Proteomics-based characterization of potential biomarkers implicated in tamoxifen 
resistance in primary operable breast cancer 
 
For this study we used a similar MS-based proteomics approach as described in paper 
III with the aim to do an unbiased search for potential predictive markers of tamoxifen 
response on tumor samples from primary BC patients.     
 
This pilot study included 24 out of the original cohort of 402 ER positive tumor 
samples from patients receiving tamoxifen as the sole adjuvant treatment. These 
samples were divided into two groups, 12 samples from patients exhibiting early 
relapses (<2 years), and 12 samples from relapse-free patients (>7 years). The groups, 
referred to as relapse and control, were matched to each other according to age, tumor 
size and node status in order to avoid the well established influence of these factors in 
outcome.  
 
Samples from tumor homogenates were prepared to be compatible to the desired 
analysis. Moreover, the digestion, labeling with iTRAQ and fractionation with IPG-IEF 
was done similarly as in paper III. Next, samples analysis was performed by LTQ-
Orbitrap Velos high resolution mass spectrometer yielding a total of 3101 identified 
proteins.  
 
As the data generated was extensive and complex advanced biostatics tools such as 
orthogal partial least square (OPLS ) and principal component analysis (PCA) were 
requires as they include efficient and robust methods for analysis and interpretation of 
data [142]. Uni- and multivariate analyses by PCA and OPLS revealed a 13-protein 
signature, which separated relapse from control group (P-value 2.2e-005). Seven of 
them were upregulated and six downregulated in the relapse group compared to the 
control group. 
 
These 13 proteins are involved in various processes such as Ca
+2
 signaling, metastasis, 
invasion, motility, EMT, and cellular metabolism [143-148]. We chose to proceed with 
the four most upregulated proteins, calcyphosine (CAPS), myxovirus resistance 1 
(MX1), Ras-related protein Rab-21 (RAB21), and glutamine--fructose-6-phosphate 
transaminase 1 (GFPT1) based on relevant biological function and applicability. 
Interestingly, expression analysis by WB on eight random patient samples out of the 24 
included in the study revealed an overexpression of CAPS and MX1 in the relapse 
group. GFPT1 was expressed at similar levels in both groups. We were not able to 
evaluate RAB21 expression due to antibody limitations. 
  
CAPS has been associated to endometrial cancer, a disease believed to be induced by 
the agonistic characteristics of tamoxifen [144, 149, 150]. CAPS is a Ca
2+
-binding 
protein whose synthesis and activation is induced by the cAMP cascade and implicated 
in cellular proliferation and differentiation [151]. This is of special interest since 
tamoxifen has been shown to bind to calmodulin, consequently inhibiting further 
functions of Ca
2+
-binding proteins through reduction of cAMP [41]. The 
overexpression of CAPS seen in the relapse patients may be the result of tamoxifen 
failure in reducing cAMP or a salvation pathway. Appropriately, signaling through 
CAPS has been suggested to be an alternative pathway to calmodulin [151].  
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The role of MX1 in cancer has not been well explored. It is known that MX1 is a 
member of the dynamin superfamily of large GTPases which mediate vesicle 
trafficking [152]. Moreover, its expression is tightly regulated by interferons, signal 
transducer and activator of transcription (STAT) signaling [153, 154] and recently also, 
the PI3K/AKT pathway [155]. Importantly, connections between MX1 and resistance 
to tamoxifen and fulvestrant, an ERD also used in BC, have been previously reported 
[156, 157]. These observations suggest that the upregulation of MX1 seen in the relapse 
group may be a consequence of induction of growth signaling through various 
pathways. 
 
Similarly, RAB21 can also interact with growth factor signaling although in an 
indirectly manner. RAB21, another GTPase, is known to regulate vesicular transport in 
cells and believed to enhance cell migration through integrin traffic modulation [158]. 
Integrins in turn, have been implicated in proliferation, survival, migration and invasion 
by conveying signals in two opposite directions, from the extracellular environment to 
the intracellular machinery and back. This is enabled by the interaction with growth 
factor signaling involving proteins such as, Ras, PI3K, and Src [159] and thus speaking 
for a potential involvement of cell motility to our findings in paper I. It is therefore of 
importance to pursue with the search of a specific antibody which will reveal the 
certainty in this statement.   
 
GFPT1 is involved in the entry of glucose into the hexosamine signaling pathway 
acting as generator of UDP N-acetylglucosamine (UDP-GlcNac). These molecules are 
recognition tags enabling the O-linked GlcNac modification which influences 
transcriptional regulation and is believed to crosstalk with phosphorylation [160]. 
Interestingly, this modification is also able to prevent ER degradation and induce STAT 
signaling [160] in turn increasing MX1 expression. Despite its theoretical potential the 
verification analysis by WB did not show variations of GFPT1 expression between 
groups. The discrepancy between quantitative MS-data and WB results could be 
explained by the detection of different protein variants by these two methods and is aim 
for further studies.    
 
In conclusion, a 13-signature characteristic of tamoxifen resistance was obtained when 
comparing patients with early relapses vs. relapse-free ones. Moreover, the two most 
upregulated proteins in the quantitative MS-data were confirmed to be overexpressed in 
patients with relapse by WB. The possible value of CAPS and MX1 as predictive 
markers for tamoxifen response will be further explored by validation in the original 
cohort and two independent ones. 
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5 GENERAL CONCLUSIONS AND FUTURE 
PERSPECTIVES 
 
The work included in this thesis shows the importance and necessity to combine the use 
of a robust and reliable high throughput method and other classical protein detection 
methods which study a few proteins at a time. The implementation of both types of 
analyzing methods is useful for the generation of hypotheses and for adding detailed 
knowledge to the big picture when trying to dissect disease mechanisms.  
 
An important drawback with many preclinical findings of tumor markers is the lack of 
consequent validation revealing their clinical usefulness. However, it is important to 
follow guidelines for tumor marker studies and to consult statisticians when doing so, 
as poor study design and inappropriate statistical analyses can lead to unreliable results 
despite having access to a large patient material.  
 
The studies presented in this thesis have increased our knowledge in molecular 
implications of tamoxifen resistance. These findings are hypothesis-generating and 
entail possible clinical implications. To explore this further, VEGF, RARA, CAPS, 
MX1 and possibly RAB21 will be validated in two independent patient populations of 
similar characteristics to the main cohort used in this thesis. These cohorts are expected 
to include 800 and 1071 consecutive ER positive patients, randomized to two years of 
tamoxifen vs. non adjuvant treatment and having received a 5-year tamoxifen regimen, 
respectively. The optimal study design for studying the true predictive value of our 
potential markers would require patients randomized between the standard 5-year 
regimen and no adjuvant treatment and thus will not be performed. However, the 
randomized cohort will enable the exploration of a true prognostic and predictive 
significance of RARA in intrinsic tamoxifen resistance.    
 
An important issue throughout the studies included in this thesis has been the lack of 
HER2 status in our most extensive cohort. In order to clarify the potential involvement 
of HER2 expression in our analyses the determination of HER2 is paramount.   
 
Another important point conveyed with this work is the utility of cell lines when 
studying tumor biology. We showed that findings from cell lines can be applied in 
patients tumors when looking for additional clues.  
 
High throughput proteomics has evolved tremendously and is continuously improving 
its reliability as tool for the discovery of new biomarkers. The implementation of 
techniques such as multiple reaction monitoring (MRM), which enables highly accurate 
targeted analysis of multiple proteins simultaneously, in the validation of our findings is 
set as a future endeavor. 
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6 CONCLUSIONS IN SUMMARY 
 
Paper I 
 
An autocrine loop through VEGF/VEGFR2 involving p38 is characteristic of 4-OHT-
resistant BC cells. 
 
Paper II 
 
High VEGF expression is significantly correlated to impaired survival in ER positive 
primary BC patients.  High VEGF-expressing tumors benefit more than low-expressing 
ones from prolonged tamoxifen treatment.  
 
Paper III 
 
High expression of RARA is significantly associated to reduced survival in patients 
treated with two years of tamoxifen. RARA is suggested to be a potential predictive 
marker for tamoxifen resistance.  
 
Paper IV 
 
CAPS and MX1 are part of a 13-protein signature characteristic of tamoxifen resistance 
in primary operable BC patients. CAPS and MX1 are potential predictive markers of 
tamoxifen response. 
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